MA40902A - Vaccins hpv16 thérapeutiques - Google Patents

Vaccins hpv16 thérapeutiques

Info

Publication number
MA40902A
MA40902A MA040902A MA40902A MA40902A MA 40902 A MA40902 A MA 40902A MA 040902 A MA040902 A MA 040902A MA 40902 A MA40902 A MA 40902A MA 40902 A MA40902 A MA 40902A
Authority
MA
Morocco
Prior art keywords
therapeutic
vaccines
hpv16 vaccines
therapeutic hpv16
nucleic acid
Prior art date
Application number
MA040902A
Other languages
English (en)
Other versions
MA40902B1 (fr
Inventor
Evelien M Bunnik
Jerôme Hhv Custers
Selina Khan
Koen Oosterhuis
Gerrit Ch Scheper
Taco Gilles Uil
Original Assignee
Janssen Vaccines & Prevention Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52020908&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA40902(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Vaccines & Prevention Bv filed Critical Janssen Vaccines & Prevention Bv
Publication of MA40902A publication Critical patent/MA40902A/fr
Publication of MA40902B1 publication Critical patent/MA40902B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20071—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Physics & Mathematics (AREA)
  • Otolaryngology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Plant Pathology (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)

Abstract

L 'invention concerne des constructions d' acides nucléiques et des polypeptides de concepteur pouvant être utilisés en tant que vaccins thérapeutiques contre hpv16.
MA40902A 2014-11-04 2015-11-03 Vaccins hpv16 thérapeutiques MA40902B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14191660 2014-11-04
PCT/EP2015/075516 WO2016071306A1 (fr) 2014-11-04 2015-11-03 Vaccins thérapeutiques contre le vph16
EP15791556.2A EP3215187B1 (fr) 2014-11-04 2015-11-03 Vaccins hpv16 thérapeutiques

Publications (2)

Publication Number Publication Date
MA40902A true MA40902A (fr) 2017-09-13
MA40902B1 MA40902B1 (fr) 2018-12-31

Family

ID=52020908

Family Applications (2)

Application Number Title Priority Date Filing Date
MA40902A MA40902B1 (fr) 2014-11-04 2015-11-03 Vaccins hpv16 thérapeutiques
MA046378A MA46378A (fr) 2014-11-04 2015-11-03 Vaccins hpv16 thérapeutiques

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA046378A MA46378A (fr) 2014-11-04 2015-11-03 Vaccins hpv16 thérapeutiques

Country Status (34)

Country Link
US (4) US9701721B2 (fr)
EP (2) EP3421046A1 (fr)
JP (2) JP6325751B2 (fr)
KR (1) KR20170083562A (fr)
CN (1) CN107075521B (fr)
AR (1) AR102527A1 (fr)
AU (2) AU2015341926B2 (fr)
BR (1) BR112017009177A2 (fr)
CA (1) CA2965562C (fr)
CL (1) CL2017001089A1 (fr)
CO (1) CO2017004838A2 (fr)
CY (1) CY1121377T1 (fr)
DK (1) DK3215187T3 (fr)
EA (1) EA035461B1 (fr)
ES (1) ES2697903T3 (fr)
HR (1) HRP20181895T1 (fr)
HU (1) HUE040440T2 (fr)
IL (1) IL251895B (fr)
LT (1) LT3215187T (fr)
MA (2) MA40902B1 (fr)
MD (1) MD3215187T2 (fr)
MX (1) MX379069B (fr)
MY (1) MY181175A (fr)
NZ (1) NZ730802A (fr)
PL (1) PL3215187T3 (fr)
PT (1) PT3215187T (fr)
RS (1) RS58080B1 (fr)
SA (1) SA517381457B1 (fr)
SG (1) SG11201702997YA (fr)
SI (1) SI3215187T1 (fr)
SM (1) SMT201800602T1 (fr)
TW (2) TWI731654B (fr)
WO (1) WO2016071306A1 (fr)
ZA (1) ZA201703055B (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS58080B1 (sr) 2014-11-04 2019-02-28 Janssen Vaccines & Prevention Bv Terapeutske vakcine protiv hpv16
JP6470872B2 (ja) 2015-08-20 2019-02-13 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． 治療用ｈｐｖ１８ワクチン
JP7053491B2 (ja) * 2016-05-02 2022-04-12 ヤンセン ファッシンズ アンド プリベンション ベーフェー 治療用ｈｐｖワクチン組み合わせ
CN106632694B (zh) * 2017-01-24 2021-02-12 南京益康生物医药有限公司 一种重组蛋白及药物组合物与应用
CA3058807A1 (fr) 2017-04-03 2018-10-11 Biontech Us Inc. Antigenes proteiques et leurs utilisations
MX2020003071A (es) 2017-09-23 2020-07-28 Boehringer Ingelheim Vetmedica Gmbh Sistema de expresion de paramyxoviridae.
WO2019164970A1 (fr) * 2018-02-20 2019-08-29 Emory University Protéines hpv, anticorps, et leurs utilisations dans la gestion de la croissance cellulaire épithéliale anormale
AU2019234549B2 (en) * 2018-03-12 2026-02-12 Sqz Biotechnologies Company Methods for treating HPV-associated diseases
EP3810277A1 (fr) * 2018-07-20 2021-04-28 Janssen Vaccines & Prevention B.V. Vecteur adénoviral recombinant exprimant un antigène zika à productivité améliorée
CN108939064B (zh) * 2018-08-06 2021-12-10 南京颂悦生物科技有限公司 基于重组减毒绵羊李斯特菌的宫颈癌治疗性疫苗
CN108992665B (zh) * 2018-08-06 2021-11-19 南京颂悦生物科技有限公司 基于重组减毒单增李斯特菌的宫颈癌治疗性疫苗
EP3935581A4 (fr) 2019-03-04 2022-11-30 Iocurrents, Inc. Compression et communication de données à l'aide d'un apprentissage automatique
US20230405105A1 (en) 2019-09-20 2023-12-21 Transgene Sa Combination of a poxvirus encoding hpv polypeptides with an anti-pd-l1 antibody
WO2021202949A2 (fr) * 2020-04-02 2021-10-07 Inovio Pharmaceuticals, Inc. Compositions et méthodes pour le traitement d'une dysplasie vulvaire
WO2021209897A1 (fr) 2020-04-13 2021-10-21 Janssen Biotech, Inc. Vaccins à base de psma et de steap1 et leurs utilisations
US20210353744A1 (en) * 2020-05-12 2021-11-18 Janssen Vaccines Prevention B.V. Administration of homologous adenoviral vectors
CA3200064A1 (fr) * 2020-11-24 2022-06-02 Ma, Muchou Joe Vaccin a adn contre le papillomavirus humain et son procede d'utilisation
JP2024539188A (ja) * 2021-10-22 2024-10-28 イノビオ ファーマシューティカルズ，インコーポレイティド 肛門高悪性度扁平上皮内病変（ｈｓｉｌ）を治療するための組成物及び方法
WO2025092908A1 (fr) * 2023-11-01 2025-05-08 仁景(苏州)生物科技有限公司 Vaccin à arnm pour le traitement de maladies associées à une infection par vph
CN120607593A (zh) * 2024-03-06 2025-09-09 诺未生物技术(无锡)有限公司 治疗hpv感染相关疾病的药物
CN118344491B (zh) * 2024-05-03 2025-02-14 华中科技大学同济医学院附属同济医院 一种hpv16/18治疗性疫苗、制备方法和应用

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0173552B1 (fr) 1984-08-24 1991-10-09 The Upjohn Company Composés recombinants d'ADN et l'expression de polypeptides comme le tPA
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
CA2017507C (fr) 1989-05-25 1996-11-12 Gary Van Nest Adjuvant constitue d'une emulsion de gouttelettes submicron d'huile
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
ATE336587T1 (de) 1994-06-10 2006-09-15 Genvec Inc Adenoviren-vektor systeme und zelllinien
US5851806A (en) 1994-06-10 1998-12-22 Genvec, Inc. Complementary adenoviral systems and cell lines
US5846782A (en) 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
US5559099A (en) 1994-09-08 1996-09-24 Genvec, Inc. Penton base protein and methods of using same
US5965541A (en) 1995-11-28 1999-10-12 Genvec, Inc. Vectors and methods for gene transfer to cells
US5786464C1 (en) 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
IL160406A0 (en) 1995-06-15 2004-07-25 Crucell Holland Bv A cell harbouring nucleic acid encoding adenoritus e1a and e1b gene products
US5837511A (en) 1995-10-02 1998-11-17 Cornell Research Foundation, Inc. Non-group C adenoviral vectors
US5891690A (en) 1996-04-26 1999-04-06 Massie; Bernard Adenovirus E1-complementing cell lines
CA2283253A1 (fr) 1997-03-04 1998-09-11 Baxter International Inc. Lignees cellulaires de complementation de la region e1 d'un adenovirus
US6020191A (en) 1997-04-14 2000-02-01 Genzyme Corporation Adenoviral vectors capable of facilitating increased persistence of transgene expression
US5972650A (en) 1997-06-26 1999-10-26 Brigham And Women's Hospital Tetracycline repressor regulated mammalian cell transcription and viral replication switch
US5981225A (en) 1998-04-16 1999-11-09 Baylor College Of Medicine Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same
US6113913A (en) 1998-06-26 2000-09-05 Genvec, Inc. Recombinant adenovirus
ES2372823T3 (es) 1999-05-17 2012-01-26 Crucell Holland B.V. Adenovirus recombinante del serotipo ad11.
WO2003104467A1 (fr) 2002-04-25 2003-12-18 Crucell Holland B.V. Moyens et procede de production de vecteurs d'adenovirus
US6913922B1 (en) 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
FR2794370B1 (fr) 1999-06-03 2003-10-17 Biovector Therapeutics Fragments proteiques polyepitopiques, leur obtention et leurs utilisations notamment en vaccination
CA2384987A1 (fr) * 1999-09-16 2001-03-22 Zycos Inc. Acides nucleiques codant pour des polypeptides de polyepitopes
DE19955558C2 (de) 1999-11-18 2003-03-20 Stefan Kochanek Permanente Amniozyten-Zelllinie, ihre Herstellung und Verwendung zur Herstellung von Gentransfervektoren
AU2002211490A1 (en) 2000-10-04 2002-04-15 The Trustees Of The University Of Pennsylvania Compositions and methods of using capsid protein from flaviviruses and pestiviruses
UA76731C2 (uk) 2000-11-23 2006-09-15 Баваріан Нордік А/С Штам mva-bn модифікованого вірусу коров'ячої віспи ankara, фармацевтична композиція, вакцина, застосування mva-bn для приготування лікарського препарату та для приготування вакцини, спосіб введення гомологічної і/або гетерологічної послідовності нуклеїнової кислоти в клітини-мішені in vitro, спосіб одержання пептиду або білка, спосіб одержання mva-bn, клітина, набір для основної/бустерної імунізації
WO2002088346A2 (fr) 2001-05-01 2002-11-07 National Research Council Of Canada Systeme destine a l'expression inductible dans des cellules eucariotes
SE0202110D0 (sv) 2002-07-05 2002-07-05 Isconova Ab Iscom preparation and use thereof
SE0301998D0 (sv) 2003-07-07 2003-07-07 Isconova Ab Quil A fraction with low toxicity and use thereof
AU2005222776A1 (en) * 2003-12-31 2005-09-29 Genimmune N.V. Inducing cellular immune responses to human papillomavirus using peptide and nucleic acid compositions
US20070207461A1 (en) 2004-02-23 2007-09-06 Crucell Holland B.V. Virus Purification Methods
KR101271884B1 (ko) 2004-11-08 2013-06-05 크로마제닉스 비.브이. 고수준으로 단백질을 발현하는 숙주세포의 선택
WO2007073513A2 (fr) 2005-11-10 2007-06-28 Genvec, Inc. Procede de propagation de vecteurs adenoviraux codant pour des produits geniques inhibiteurs
CN103122360A (zh) 2006-02-28 2013-05-29 瓦克萨特公司 嵌合腺病毒载体
WO2007104792A2 (fr) 2006-03-16 2007-09-20 Crucell Holland B.V. Adénovirus recombinés basés sur les sérotypes 26 et 48 et utilisation de ceux-ci
CL2008000249A1 (es) * 2007-01-30 2008-05-30 Transgene Sa Uso de una molecula de acido nucleico que codifica al menos un polipeptido e2 del papilomavirus, un vector o una particula virica infecciosa que la comprenda para tratar una infeccion permanente por papilomavirus causada por al menos un papilomavirus
DE102008010954A1 (de) * 2008-02-25 2009-08-27 Cichon, Günter, Prof.Dr. DNA-Vakzine zur Therapie und Prophylaxe von Gebärmutterhalskrebs und seinen prämalignen Vorstufen
US10041049B2 (en) 2008-11-03 2018-08-07 Janssen Vaccines & Prevention B.V. Method for the production of adenoviral vectors
GB0823497D0 (en) 2008-12-24 2009-01-28 Isis Innovation Immunogenic composition and use thereof
MX2012007936A (es) 2010-02-15 2012-11-22 Crucell Holland Bv Metodo para la produccion de vectores adenovirales del serotipo 26 del adenovirus.
PL2604629T3 (pl) * 2010-08-13 2018-08-31 Genexine, Inc. Kompozycja do zapobiegania lub leczenia raka szyjki macicy ze wzmacniaczem odporności przeciwko wirusowi brodawczaka ludzkiego
US20130122038A1 (en) 2011-11-14 2013-05-16 The United States Of America As Represented By The Secretary Of The Department Heterologous prime-boost immunization using measles virus-based vaccines
EP2601968A1 (fr) * 2011-12-06 2013-06-12 Deutsches Krebsforschungszentrum Acides polynucléiques dérivés du VPH pour thérapie
US8932607B2 (en) 2012-03-12 2015-01-13 Crucell Holland B.V. Batches of recombinant adenovirus with altered terminal ends
US9119813B2 (en) 2012-03-22 2015-09-01 Crucell Holland B.V. Vaccine against RSV
EP3188752A2 (fr) 2014-09-03 2017-07-12 Bavarian Nordic A/S Virus contre les filovirus à base du virus de la vaccine ankara modifié recombinant (mva)
RS58080B1 (sr) 2014-11-04 2019-02-28 Janssen Vaccines & Prevention Bv Terapeutske vakcine protiv hpv16
JP6470872B2 (ja) * 2015-08-20 2019-02-13 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． 治療用ｈｐｖ１８ワクチン
JP7053491B2 (ja) * 2016-05-02 2022-04-12 ヤンセン ファッシンズ アンド プリベンション ベーフェー 治療用ｈｐｖワクチン組み合わせ

Also Published As

Publication number Publication date
LT3215187T (lt) 2018-12-27
AU2015341926A1 (en) 2017-04-27
ES2697903T3 (es) 2019-01-29
SG11201702997YA (en) 2017-05-30
CA2965562A1 (fr) 2016-05-12
HUE040440T2 (hu) 2019-03-28
CN107075521A (zh) 2017-08-18
WO2016071306A1 (fr) 2016-05-12
PT3215187T (pt) 2018-11-27
EA201790976A1 (ru) 2017-09-29
CO2017004838A2 (es) 2017-07-28
BR112017009177A2 (pt) 2018-12-11
US20180344841A1 (en) 2018-12-06
JP6606571B2 (ja) 2019-11-13
JP2018148890A (ja) 2018-09-27
TW202043476A (zh) 2020-12-01
EP3421046A1 (fr) 2019-01-02
MA46378A (fr) 2019-08-07
US20170281747A1 (en) 2017-10-05
TWI694147B (zh) 2020-05-21
US10071151B2 (en) 2018-09-11
SMT201800602T1 (it) 2019-01-11
EA035461B1 (ru) 2020-06-19
US20160122396A1 (en) 2016-05-05
ZA201703055B (en) 2019-11-27
MY181175A (en) 2020-12-21
MX379069B (es) 2025-03-10
IL251895A0 (en) 2017-06-29
MA40902B1 (fr) 2018-12-31
EP3215187A1 (fr) 2017-09-13
AR102527A1 (es) 2017-03-08
JP6325751B2 (ja) 2018-05-16
SI3215187T1 (sl) 2019-02-28
CN107075521B (zh) 2021-06-08
US9701721B2 (en) 2017-07-11
KR20170083562A (ko) 2017-07-18
MD3215187T2 (ro) 2019-02-28
RS58080B1 (sr) 2019-02-28
NZ730802A (en) 2021-12-24
AU2015341926B2 (en) 2018-09-27
TW201617450A (zh) 2016-05-16
CL2017001089A1 (es) 2017-12-29
AU2018282463B2 (en) 2020-09-10
JP2017534286A (ja) 2017-11-24
EP3215187B1 (fr) 2018-08-29
US20200164057A1 (en) 2020-05-28
SA517381457B1 (ar) 2021-03-11
CA2965562C (fr) 2023-11-21
US11040096B2 (en) 2021-06-22
TWI731654B (zh) 2021-06-21
DK3215187T3 (en) 2018-12-10
IL251895B (en) 2019-08-29
HRP20181895T1 (hr) 2019-01-11
PL3215187T3 (pl) 2019-04-30
US10555996B2 (en) 2020-02-11
CY1121377T1 (el) 2020-05-29
AU2018282463A1 (en) 2019-01-24
MX2017005788A (es) 2017-08-02

Similar Documents

Publication Publication Date Title
MA40902A (fr) Vaccins hpv16 thérapeutiques
PH12019501931A1 (en) Anti-pdl1 antibody formulations
CY1124407T1 (el) Ενωσεις αναστολεα αυτοταξινης
CY1124131T1 (el) Συζευγματα αντι-ρτκ7 αντισωματος-φαρμακου
BR112018003019A2 (pt) vacinas terapêuticas contra hpv18
MA40938A (fr) Anticorps anti-cd79b et méthodes d'utilisation desdits anticorps
MA40579A (fr) Anticorps anti-cll-1 et immunoconjugués
HUE057877T2 (hu) Vegyületek és készítmények terápiás szerek intracelluláris bejuttatására
MA40576B1 (fr) Anticorps et immunoconjugués anti-her2
MX421186B (es) Constructos de anticuerpos.
MX2019013670A (es) Formulaciones de anticuerpos y proteinas.
MX2016015162A (es) Anticuerpos anti - gpc3 e inmunoconjugados.
MX2017003121A (es) Formulaciones de anticuerpos.
MX2016014306A (es) Marcadores para terapia con lipoproteinas de alta densidad (hdl).
MX2017004473A (es) Formulaciones de betalactamasa y usos de las mismas.
EP3558000C0 (fr) Compositions contenant de l'acide acétique et de l'acide hypochloreux
IL263574A (en) Calr and jak2 vaccine compositions
EP3454908A4 (fr) Constructions ciblées et leurs formulations
EA201791454A1 (ru) Лекарственные формы для трансдермального введения
MX2020012893A (es) Formulaciones de proteinas.
EP3512839A4 (fr) Inhibiteurs de yap1 ciblant l'interaction de yap1 avec oct4
EP3394099A4 (fr) Formulations d'anticorps anti-il-10 modifiés
CL2019002733A1 (es) Formulaciones de clorhidrato del ácido 1-amino-1-ciclopropanocarboxílico.
MX2022005888A (es) Metodos para tratar afecciones oculares.
MY190102A (en) Tolerogenic dna vaccine